lobbying_activities
Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API
242 rows where filing_period = "second_quarter", filing_year = 2017 and issue_code = "PHA" sorted by filing_year descending
This data as json, CSV (advanced)
Suggested facets: filing_type, income_amount, is_termination, received_date (date)
| id | filing_uuid | filing_type | registrant_name | registrant_id | client_name | filing_year ▲ | filing_period | issue_code | specific_issues | government_entities | income_amount | expense_amount | is_no_activity | is_termination | received_date |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1982474 | MR. BRIAN KELLY 3055e158-1468-402f-adf1-3fce81115852 | Q2 | MR. BRIAN KELLY | 40024191 | LUNDBECK PHARMACEUTICALS | 2017 | second_quarter | PHA | CNS Brain Disorders Alzheimer's | HOUSE OF REPRESENTATIVES,SENATE | 15000 | 0 | 0 | 2017-06-30T10:55:16.673000-04:00 | |
| 1982947 | WELLINGTON STRATEGIES, LLC. 1b903b62-5c13-4521-b7fb-9af47ef27b58 | Q2 | WELLINGTON STRATEGIES, LLC. | 401104410 | OMNICELL, INC. | 2017 | second_quarter | PHA | Regulations pertaining to the Drug Quality and Security Act (Public Law No: 113-54) | Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office | 15000 | 0 | 0 | 2017-07-05T10:01:32.560000-04:00 | |
| 1983215 | AMERICAN AMBULANCE ASSOCIATION c912fff0-ad65-41a4-a27b-30e879858069 | Q2 | AMERICAN AMBULANCE ASSOCIATION | 56018 | AMERICAN AMBULANCE ASSOCIATION | 2017 | second_quarter | PHA | Lobbied for passage of Protecting Patient Access to Emergency Medication Act (H.R. 304, S. 916). | Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE | 280000 | 0 | 0 | 2017-07-05T17:00:49.500000-04:00 | |
| 1983388 | AMERICAN COLLEGE OF CLINICAL PHARMACY 55f83551-dc10-499b-87c1-0eb70db2ca35 | Q2 | AMERICAN COLLEGE OF CLINICAL PHARMACY | 57258 | AMERICAN COLLEGE OF CLINICAL PHARMACY | 2017 | second_quarter | PHA | Coverage for direct patient care services of qualified pharmacists under Medicare and other public health programs. | Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE | 128375 | 0 | 0 | 2017-07-06T12:18:21.283000-04:00 | |
| 1983547 | INDEPENDENT PHARMACY COOPERATIVE ff0bc16d-bc60-4eb9-84aa-ca96dced8007 | Q2 | INDEPENDENT PHARMACY COOPERATIVE | 313098 | INDEPENDENT PHARMACY COOPERATIVE | 2017 | second_quarter | PHA | Support S. 109/H.R. 592, the Pharmacy and Medically Underserved Areas Enhancement Act Support S.413/H.R. 1038, the "Improving Transparency and Accuracy in Medicare Part D Drug Spending Act. Ensure patient choice in Comprehensive Addiction and Recovery Act of 2016 lock-in provision. Support Affordable Care Act of 2010 Average Manufacturer Price methodology. | Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2017-07-06T15:35:00.467000-04:00 | |
| 1983548 | STANTON PARK GROUP 6f1b8a3c-3ee9-4848-9fd2-89eebac44271 | 2T | STANTON PARK GROUP | 83717 | OSH'S NOT FOR PROFIT PHARMACEUTICALS | 2017 | second_quarter | PHA | information gathering regarding pharmaceutical compounding | Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE | 10000 | 0 | 1 | 2017-07-06T15:36:01.903000-04:00 | |
| 1983674 | AMERICAN CAPITOL GROUP 19103d00-b163-411a-ad14-5076c79ec73a | Q2 | AMERICAN CAPITOL GROUP | 305852 | CARDINAL HEALTH | 2017 | second_quarter | PHA | Issues Related to Distribution and Sale of Pharmaceutical and Medical Products and Services; | HOUSE OF REPRESENTATIVES,SENATE | 25000 | 0 | 0 | 2017-07-06T17:09:11.363000-04:00 | |
| 1983682 | AMERICAN CAPITOL GROUP eabaa3a7-f07d-4638-90b2-36423cf89163 | 2A | AMERICAN CAPITOL GROUP | 305852 | CARDINAL HEALTH | 2017 | second_quarter | PHA | Issues Related to Distribution and Sale of Pharmaceutical and Medical Products and Services; | Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 25000 | 0 | 0 | 2017-07-06T17:16:17.237000-04:00 | |
| 1983848 | AMERICAN SOCIETY FOR DERMATOLOGIC SURGERY ASSOCIATION 9f4a8bef-4022-4d2f-9ac2-f9a636f88622 | Q2 | AMERICAN SOCIETY FOR DERMATOLOGIC SURGERY ASSOCIATION | 401103437 | AMERICAN SOCIETY FOR DERMATOLOGIC SURGERY ASSOCIATION | 2017 | second_quarter | PHA | Determining the intended use of drugs and/or devices and using scientific exchange to share data on "Off-label use" (HR 1703/Medical Products Communications Act of 2017) | Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE | 0 | 0 | 2017-07-07T11:45:34.467000-04:00 | ||
| 1984096 | PENN AVENUE PARTNERS 1a10336a-f323-4117-a63b-6c7b82af5aee | Q2 | PENN AVENUE PARTNERS | 400918672 | PURDUE PHARMA L.P. | 2017 | second_quarter | PHA | Monitoring legislative and regulatory activities impacting the pharmaceutical industry. | SENATE | 60000 | 0 | 0 | 2017-07-07T17:50:48.440000-04:00 | |
| 1984452 | RED+BLUE STRATEGIES 28655048-411c-421a-9cbd-0faba9398dd3 | Q2 | RED+BLUE STRATEGIES | 400693064 | EXPRESS SCRIPTS INC. | 2017 | second_quarter | PHA | S. 637 - Creating Transparency to have Prescription Drug Rebates Unlocked - Issues related to the alleged relationship between rebates and drug prices. S. 771 - A bill to Improve Access to Affordable Prescription Drugs - Issue related to bringing drug pricing down including better policies in the Part D coverage gap, couponing and advancing biosimilars. H.R. 281- National Defense Authorization Act for FY 2018- Issues related to prescription medications for military personnel and their families. | Executive Office of the President (EOP),HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2017-07-10T13:37:04.490000-04:00 | |
| 1984497 | RED+BLUE STRATEGIES d8f34a85-2ea2-4807-ad4e-9fbfc4068fd6 | Q2 | RED+BLUE STRATEGIES | 400693064 | PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION (PCMA) | 2017 | second_quarter | PHA | S. 637 - Creating Transparency to Have Prescription Drug Rebates Unlocked - Issues related to the alleged relationship between rebates and drug prices. S. 771 - A Bill to Improve Access to Affordable Prescription Drugs - Issues related to bringing drug prices down including strengthening policies in the Part D coverage gap, couponing and advancing biosimilars. S. 934 - The FDA Reauthorization Act of 2017 - potential new policies related to prescription drug pricing, efficacy and delivery. H.R. 2430 - The FDA Reauthorization Act of 2017 - potential new policies related to prescription drug pricing, efficacy, and delivery. Issues related to the price of prescription medications in the United States. | Executive Office of the President (EOP),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE | 60000 | 0 | 0 | 2017-07-10T14:04:59.903000-04:00 | |
| 1984555 | RED+BLUE STRATEGIES fac8943f-589a-4fb2-b2cf-f3e2c2750568 | Q2 | RED+BLUE STRATEGIES | 400693064 | PEW CHARITABLE TRUSTS | 2017 | second_quarter | PHA | S. 934 - The FDA Reauthorization Act of 2017 - potential new policies related to prescription drug pricing, efficacy and delivery. H.R. 2430 - The FDA Reauthorization Act of 2017 - potential new policies related to prescription drug pricing, efficacy, and delivery. S. 1334/H.R. 2797 - Patient Choice and Quality Care Act of 2017 - Issues related to better integration of end-of-life and palliative care into the nation's health care system. H.R. 2871 - The Preserving Patient Access to Compounded Medications Act of 2017 - Concerns about how the bill could compromise safety protocols for compounded medications. Issues related to antibiotic innovation and advancement. Issues related opioid abuse and methods to fight against the opioid epidemic in the United States. Issues related to ensuring the safety of compounded medications. Issues related to over the counter medications and supplements. Issues related to the Physician Payment Sunshine Act and the Open Payments system. | HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2017-07-10T14:44:54.160000-04:00 | |
| 1984603 | WAXMAN STRATEGIES 516364b9-a563-41bd-9cbb-4ed84ba1923b | Q2 | WAXMAN STRATEGIES | 401103693 | 340B HEALTH | 2017 | second_quarter | PHA | Issues affecting the 340B drug pricing program | HOUSE OF REPRESENTATIVES | 18750 | 0 | 0 | 2017-07-10T15:06:35.687000-04:00 | |
| 1984730 | MCDERMOTT+ LLC ba828b8b-c3bf-4a76-b728-7cf992e9b8b7 | Q2 | MCDERMOTT+ LLC | 401103287 | ALLIANCE FOR RURAL HOSPITAL ACCESS | 2017 | second_quarter | PHA | Amendments to Section 340B of the Public Health Service Act to gain eligibility for rural referral centers and sole community hospitals in the federal discount drug purchasing program. | Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2017-07-10T17:02:56.340000-04:00 | |
| 1985239 | PD FRAZER CONSULTING, INC. 722bc2a8-684b-4438-9c67-7d2d5cf6122c | Q2 | PD FRAZER CONSULTING, INC. | 65998 | CANADA INTERNATIONAL PHARMACY ASSOCIATION | 2017 | second_quarter | PHA | Support intent of H.R.1480 Safe and Affordable Drugs from Canada Act of 2017 Support intent of S.92 Safe and Affordable Drugs from Canada Act of 2017 Support intent of H.R. Affordable and Safe Prescription Drug Importation Act Support of S.469 Affordable and Safe Prescription Drug Importation Act | HOUSE OF REPRESENTATIVES,SENATE | 40000 | 0 | 0 | 2017-07-11T15:33:51.513000-04:00 | |
| 1985756 | COUNCIL FOR CITIZENS AGAINST GOVERNMENT WASTE eb355345-7deb-409b-9383-f8565185f57a | Q2 | COUNCIL FOR CITIZENS AGAINST GOVERNMENT WASTE | 11003 | COUNCIL FOR CITIZENS AGAINST GOVERNMENT WASTE | 2017 | second_quarter | PHA | Oppose S. 637 | HOUSE OF REPRESENTATIVES,SENATE | 70000 | 0 | 0 | 2017-07-12T12:46:36.527000-04:00 | |
| 1986313 | RUBIN AND RUDMAN LLP f50d68f0-83bc-45de-8602-167dcb834893 | Q2 | RUBIN AND RUDMAN LLP | 400942719 | BLINK HEALTH LTD (A BERMUDA LIMITED COMPANY) | 2017 | second_quarter | PHA | Advocate for client before members of the U.S. House of Representatives, U.S. Senate, and staffs to each, with respect to market based solutions to drug pricing and chain pharmacy barriers to generic pharmaceutical price reduction. | HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2017-07-13T10:32:21.423000-04:00 | |
| 1986601 | RED+BLUE STRATEGIES f9557be6-ef58-4ba9-a51e-0b37f2cbf16e | Q2 | RED+BLUE STRATEGIES | 400693064 | BLUE CROSS BLUE SHIELD OF MASSACHUSETTS | 2017 | second_quarter | PHA | Issues related to curbing the abuse of opioids in the United States. | Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2017-07-13T12:32:19.080000-04:00 | |
| 1986622 | RED+BLUE STRATEGIES 7830c1a3-b481-425a-ba64-4874b49489e9 | Q2 | RED+BLUE STRATEGIES | 400693064 | COHERUS BIOSCIENCES | 2017 | second_quarter | PHA | S. 771 - A bill to improve access to affordable prescription drugs - issues related to ensuring a healthy market for biosimilar medications. S.934 - FDA Reauthorization Act of 2017 - All issues related to the development and marketing of biosimilar medications. H.R. 2797 - FDA Reauthorization Act of 2017 - All issues related to the development and marketing of biosimilar medications. Issues related to the treatment of biosimilar medications in Medicare Part B and D programs. Issues related to the maintenance of current IPR laws. | Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE | 60000 | 0 | 0 | 2017-07-13T13:01:35.477000-04:00 | |
| 1986690 | KATE MOSS f2027c0a-1de3-4650-a6d2-f915d135bb07 | Q2 | KATE MOSS | 25988 | CVS HEALTH | 2017 | second_quarter | PHA | Legislation impacting PBMs and drug pricing | HOUSE OF REPRESENTATIVES,SENATE | 40000 | 0 | 0 | 2017-07-13T14:10:41.623000-04:00 | |
| 1986744 | PARRY, ROMANI, DECONCINI & SYMMS ae5411c5-82a2-4423-9f84-da90bfaac33b | Q2 | PARRY, ROMANI, DECONCINI & SYMMS | 30792 | ROCK & ASSOCIATES | 2017 | second_quarter | PHA | Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. H.R. 2871, Preserving Patient Access to Compounded Medications Act of 2017. | HOUSE OF REPRESENTATIVES,SENATE | 12000 | 0 | 0 | 2017-07-13T14:49:19.330000-04:00 | |
| 1986780 | NELSON MULLINS RILEY & SCARBOROUGH b287a294-f7dd-4ccd-a766-a6820adf8cda | Q2 | NELSON MULLINS RILEY & SCARBOROUGH | 285871 | CASCADE HEMOPHILIA CONSORTIUM | 2017 | second_quarter | PHA | Issues related to 340B Drug Pricing Program | HOUSE OF REPRESENTATIVES,SENATE | 20000 | 0 | 0 | 2017-07-13T15:07:48.780000-04:00 | |
| 1986789 | NELSON MULLINS RILEY & SCARBOROUGH 2148bf11-3e21-4bff-b2dd-7a7272ee9cba | Q2 | NELSON MULLINS RILEY & SCARBOROUGH | 285871 | HEMOPHILIA OF GEORGIA | 2017 | second_quarter | PHA | Issues related to the 340B Drug Pricing Program and the proposed American Health Care Act | HOUSE OF REPRESENTATIVES,SENATE | 20000 | 0 | 0 | 2017-07-13T15:08:54.140000-04:00 | |
| 1987935 | HOLLAND & KNIGHT LLP 26d88045-a41a-42d0-b6b2-801894062fdf | Q2 | HOLLAND & KNIGHT LLP | 18466 | THE BIOSIMILARS FORUM | 2017 | second_quarter | PHA | Medicare reimbursement issues, FDA regulation of biosimilars; S. 934, H.R. 2430, the FDA Reauthorization Act of 2017. | Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE | 120000 | 0 | 0 | 2017-07-14T15:53:47.137000-04:00 | |
| 1988011 | MCGUIREWOODS CONSULTING (A SUBSIDIARY OF MCGUIREWOODS LLP) 08a06000-9871-4030-8644-00e6db970845 | Q2 | MCGUIREWOODS CONSULTING (A SUBSIDIARY OF MCGUIREWOODS LLP) | 24486 | INOVIO PHARMACEUTICALS | 2017 | second_quarter | PHA | Government Relations Services including developing strategies to achieve legislative goals | HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2017-07-14T16:57:55.560000-04:00 | |
| 1988111 | ROCK & ASSOCIATES 683a2686-d2ac-471c-ad6f-321cd72f36bf | Q2 | ROCK & ASSOCIATES | 33545 | BRAIDWOOD MANAGEMENT, INC. | 2017 | second_quarter | PHA | Issues pertaining to pharmacy compounding. H.R. 2871, Patient Access to Compounded Medications Act of 2017. | HOUSE OF REPRESENTATIVES,SENATE | 11250 | 0 | 0 | 2017-07-15T11:05:36.160000-04:00 | |
| 1988115 | ROCK & ASSOCIATES 3256e429-ce0d-4246-9b64-204ca197d884 | Q2 | ROCK & ASSOCIATES | 33545 | DIAMONDBACK DRUGS | 2017 | second_quarter | PHA | Legislation pertaining to pharmacy compounding. H.R. 2871, Patient Access to Compounded Medications Act of 2017. | HOUSE OF REPRESENTATIVES,SENATE | 11250 | 0 | 0 | 2017-07-15T11:07:38.350000-04:00 | |
| 1988117 | ROCK & ASSOCIATES 9c310cd0-d52b-4fa0-96f1-bd60a847a632 | Q2 | ROCK & ASSOCIATES | 33545 | VETERINARY PHARMACIES OF AMERICA, INC. | 2017 | second_quarter | PHA | Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. H.R. 2871, Patient Access to Compounded Medications Act of 2017. | HOUSE OF REPRESENTATIVES,SENATE | 11250 | 0 | 0 | 2017-07-15T11:09:40.273000-04:00 | |
| 1988121 | ROCK & ASSOCIATES 13e638d3-0657-4270-9d50-f49d977f84c7 | Q2 | ROCK & ASSOCIATES | 33545 | WEDGEWOOD VILLAGE PHARMACY, INC. | 2017 | second_quarter | PHA | Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. H.R. 2871, Patient Access to Compounded Medications Act of 2017. | HOUSE OF REPRESENTATIVES,SENATE | 11250 | 0 | 0 | 2017-07-15T11:11:42.307000-04:00 | |
| 1988124 | ROCK & ASSOCIATES 37443b5d-7728-47df-857b-af71348d9cd4 | Q2 | ROCK & ASSOCIATES | 33545 | WOMEN'S INTERNATIONAL PHARMACY | 2017 | second_quarter | PHA | Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. H.R. 2871, Patient Access to Compounded Medications Act of 2017. | HOUSE OF REPRESENTATIVES,SENATE | 11250 | 0 | 0 | 2017-07-15T11:12:43.823000-04:00 | |
| 1988127 | ROCK & ASSOCIATES db4f9046-4456-4e2f-b990-5dff779fa1af | Q2 | ROCK & ASSOCIATES | 33545 | WELLNESS PHARMACY | 2017 | second_quarter | PHA | Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. H.R. 2871, Patient Access to Compounded Medications Act of 2017. | HOUSE OF REPRESENTATIVES,SENATE | 11250 | 0 | 0 | 2017-07-15T11:13:47.837000-04:00 | |
| 1988221 | THE D MAJOR GROUP dc2dbf8e-fa53-4676-ba93-811c01f69e26 | Q2 | THE D MAJOR GROUP | 401103162 | CVS CAREMARK | 2017 | second_quarter | PHA | Advocate for the protection of pharmaceutical benefit management and resulting cost savings. | HOUSE OF REPRESENTATIVES,SENATE | 34500 | 0 | 0 | 2017-07-16T00:18:42.963000-04:00 | |
| 1988337 | BROYDRICK & ASSOCIATES fe4331e7-aa07-4397-97c4-355bfbab5975 | Q2 | BROYDRICK & ASSOCIATES | 7268 | TONIX PHARMACEUTICALS | 2017 | second_quarter | PHA | Funding for a new drug for PTSD. | Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2017-07-16T20:11:08.307000-04:00 | |
| 1988738 | PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION 825e21dc-0760-4fcb-b7ce-5eab84c35bec | Q2 | PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION | 31348 | PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION | 2017 | second_quarter | PHA | Issues related to pharmacy contracting with respect to drug pricing and pharmacy networks. Regulatory and proposed legislative changes to Medicare Part D pharmacy contracting, Direct and Indirect Remuneration (DIR), pharmacy networks, and mail-service pharmacy. Issues related to the management of Medicaid prescription drug benefits. Issues related to prescription drug abuse. Provisions of PL 111-148 and PL 111-152 impacting Medicare Part D such as PBM disclosure provisions, implementation of the prescriber registration rules and definition of negotiated price. HR.1038/S.413, Improving Transparency and Accuracy in Part D Spending Act H.R.1316, Prescription Drug Price Transparency Act S.637, Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017 S.771, Improving Access to Affordable Prescription Drug Act H.R.1939/S.1044, Ensuring Seniors Access to Local Pharmacies Act | Centers For Medicare and Medicaid Services (CMS),Executive Office of the President (EOP),Federal Trade Commission (FTC),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Medicare Payment Advisory Commission (MedPAC),Office of Management & Budget (OMB),SENATE | 763533 | 0 | 0 | 2017-07-17T11:01:45.610000-04:00 | |
| 1988833 | NOVO NORDISK INC. bd4f9eee-3900-4f08-b3e4-24d54addeac4 | Q2 | NOVO NORDISK INC. | 284790 | NOVO NORDISK INC. | 2017 | second_quarter | PHA | Issues related to H.R. 2430/S. 934 FDA Reauthorization Act of 2017 (Prescription Drug User Fee Act VI); H.R. 1245/S. 469 Affordable and Safe Prescription Drug Importation Act; H.R. 1776/S.771 Improving Access To Affordable Prescription Drugs Act; issues related to 340B program | Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Economic Council (NEC),SENATE | 830000 | 0 | 0 | 2017-07-17T11:30:45.490000-04:00 | |
| 1988855 | AMERICAN VETERINARY MEDICAL ASSOCIATION 3539675f-dcc7-4d3d-a4e8-ff11f0391368 | Q2 | AMERICAN VETERINARY MEDICAL ASSOCIATION | 3630 | AMERICAN VETERINARY MEDICAL ASSOCIATION | 2017 | second_quarter | PHA | H.R. 623, Fairness to Pet Owners Act Veterinary Compounding Draft Legislation Discussions with Congressional staff and FDA to express the need for compounding of medications for use in animals and FDA's draft GFI #230 Discussions with DEA regarding use of controlled substances by veterinary practitioners, transportation of controlled substances, telemedicine and prescription monitoring programs. | Agriculture, Dept of (USDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Justice, Dept of (DOJ),SENATE | 200000 | 0 | 0 | 2017-07-17T11:31:50.880000-04:00 | |
| 1988964 | SQUIRE PATTON BOGGS 2f914476-aead-44f7-a524-1f8e8e28a152 | Q2 | SQUIRE PATTON BOGGS | 30906 | BIOTECHNOLOGY INNOVATION ORGANIZATION | 2017 | second_quarter | PHA | Monitoring legislation that could impact pharmaceutical industry. | HOUSE OF REPRESENTATIVES,SENATE | 80000 | 0 | 0 | 2017-07-17T11:56:02.807000-04:00 | |
| 1989061 | BUCHANAN INGERSOLL & ROONEY PC 22a2a737-9278-478c-8e56-f3d5af8591af | Q2 | BUCHANAN INGERSOLL & ROONEY PC | 55291 | 60 DEGREES PHARMACEUTICALS | 2017 | second_quarter | PHA | Government relations services relating to priority review voucher within the user fee reauthorization legislation. | HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2017-07-17T12:28:23.137000-04:00 | |
| 1989151 | CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. 99461f34-0edf-49ff-bb35-8bb4cbbd0703 | Q2 | CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. | 8511 | AMERICAN SOCIETY OF HEMATOLOGY | 2017 | second_quarter | PHA | HR 1409, Cancer Drug Coverage Parity Act | Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE | 30000 | 0 | 0 | 2017-07-17T13:07:24.303000-04:00 | |
| 1989156 | CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. 81917821-edd5-45e4-9813-9b04e81e8a8a | Q2 | CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. | 8511 | THE HEMOPHILIA ALLIANCE | 2017 | second_quarter | PHA | Issues related to the 340B drug discount program | Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2017-07-17T13:09:25.990000-04:00 | |
| 1989162 | CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. f330ee14-120f-4f0c-80dd-907a2abf7929 | Q2 | CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. | 8511 | NATIONAL HEMOPHILIA FOUNDATION | 2017 | second_quarter | PHA | Issues related to hemophilia treatments, specialty pharmacies and the 340B drug purchasing programs. | Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE | 50000 | 0 | 0 | 2017-07-17T13:10:29.507000-04:00 | |
| 1989171 | CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. 608b3b91-7921-416a-bfad-dc09258a4834 | Q2 | CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. | 8511 | NATIONAL ASSOCIATION OF EPILEPSY CENTERS | 2017 | second_quarter | PHA | Issues related to anti-epileptic drugs. | Agency for Healthcare Research & Quality (AHRQ),Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE | 10000 | 0 | 0 | 2017-07-17T13:11:30.647000-04:00 | |
| 1989282 | SAFEWAY INC. c94ba27c-4424-40c3-a306-448f97f9fdf4 | Q2 | SAFEWAY INC. | 300173 | SAFEWAY | 2017 | second_quarter | PHA | H.R. 592, S. 109 - The Pharmacy and Medically Underserved Areas Enhancement Act, all provisions. H.R. 1038/S. 413 - Improving Transparency and Accuracy in Medicare Part D Spending Act, all provisions. H.R. 2430 - FDA Reauthorization Act of 2017, amendments related to importation of prescription drugs Implementation of 2017 NDAA Tricare Pilot. | HOUSE OF REPRESENTATIVES,SENATE | 80000 | 0 | 0 | 2017-07-17T13:51:32.467000-04:00 | |
| 1989360 | ASSOCIATION OF NATIONAL ADVERTISERS, INC. 58626d71-5430-4907-ac76-1317ed8a34e4 | Q2 | ASSOCIATION OF NATIONAL ADVERTISERS, INC. | 4653 | ASSOCIATION OF NATIONAL ADVERTISERS, INC. | 2017 | second_quarter | PHA | Proposals relating to the regulation of direct-to-consumer prescription drug advertising | Federal Communications Commission (FCC),HOUSE OF REPRESENTATIVES,Natl Economic Council (NEC),SENATE,Treasury, Dept of | 430000 | 0 | 0 | 2017-07-17T14:08:28.857000-04:00 | |
| 1989589 | NATIONAL NURSES UNITED c67acff4-d2ce-44d9-9a1e-075753262e27 | Q2 | NATIONAL NURSES UNITED | 40021153 | NATIONAL NURSES UNITED | 2017 | second_quarter | PHA | H.R. 1245 - support for Affordable & Safe Prescription Drug Importation Act H.R. 1776 - support for Improving Access to Affordable Prescription Drugs Act | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2017-07-17T14:49:07.517000-04:00 | |
| 1989668 | MEHLMAN CONSULTING, INC. 0c5ff2c9-8a96-47b2-b1fe-652508e3ef89 | Q2 | MEHLMAN CONSULTING, INC. | 284950 | VIRTUS PHARMACEUTICALS LLC | 2017 | second_quarter | PHA | FDA Drug Approval | HOUSE OF REPRESENTATIVES,SENATE | 10000 | 0 | 0 | 2017-07-17T14:59:59.190000-04:00 | |
| 1989970 | NATIONAL ASSOCIATION FOR THE ADVANCEMENT OF COLORED PEOPLE a92cea2a-21be-471c-bc80-72a8a9abd472 | Q2 | NATIONAL ASSOCIATION FOR THE ADVANCEMENT OF COLORED PEOPLE | 48975 | NATIONAL ASSOCIATION FOR THE ADVANCEMENT OF COLORED PEOPLE | 2017 | second_quarter | PHA | Support maintaining ACA Patient Protections and Access to Prescription drugs Support S. 469 / HR 1245, the Affordable and Safe Prescription Drug Importation Act Support Klobuchar Amendment #178 to S. Con. 3 which established a deficit neutral fund relating to lower drug prices for Americans by importing prescription drugs from Canada. Support Wyden amendment #188 to S Con Res 3 creating a point of order against legislation that does not lower drug prices. | Agriculture, Dept of (USDA),Bureau of Alcohol Tobacco Firearms & Explosives,Centers For Medicare and Medicaid Services (CMS),Consumer Financial Protection Bureau (CFPB),Education, Dept of,Election Assistance Commission (EAC),Environmental Protection Agency (EPA),Equal Employment Opportunity Commission (EEOC),Federal Communications Commission (FCC),Federal Housing Finance Agency (FHFA),Federal Motor Carrier Safety Administration,Federal Reserve System,Health & Human Services, Dept of (HHS),Homeland Security, Dept of (DHS),HOUSE OF REPRESENTATIVES,Housing & Urban Development, Dept of (HUD),Justice, Dept of (DOJ),Labor, Dept of (DOL),Natl Park Service (NPS),Office of Management & Budget (OMB),Office of the Comptroller of the Currency (OCC),Securities & Exchange Commission (SEC),SENATE,Social Security Administration (SSA),State, Dept of (DOS),Transportation, Dept of (DOT),Treasury, Dept of,White House Office | 70000 | 0 | 0 | 2017-07-17T15:55:14.230000-04:00 | |
| 1989985 | AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS 07ed27e8-7a56-4e95-9374-37487608c696 | Q2 | AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS | 3457 | AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS | 2017 | second_quarter | PHA | Contact concerning FDA authority to manage drug shortages, regulation of pharmacy compounding, implementation of the Drug Quality and Security Act. Communication with FDA on Generic Drug User Fee Act, Prescription Drug user Fee Act, Biosimilar User Fee Act, and electronic drug information. Contact on manufacturing gaming REMS to gain market advantage and drug importation. Communication with Congress on off-label use. Contact on the 340B program. | Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Labor, Dept of (DOL),SENATE | 270000 | 0 | 0 | 2017-07-17T15:56:23.167000-04:00 | |
| 1990219 | POWERS PYLES SUTTER & VERVILLE, P.C. e64d13d8-434e-42c1-9604-00126f78197c | Q2 | POWERS PYLES SUTTER & VERVILLE, P.C. | 32008 | 340B HEALTH | 2017 | second_quarter | PHA | Section 340B of the Public Health Services Act, Section 1927 of the Social Security Act and issues related to (1) administration and Congressional oversight of the 340B Drug Discount Program, (2) implementation of 340B-related provisions in the Patient Protection and Affordable Care Act of 2010, and (3)finding of the Health Resources and Services Administration (HRSA) under the Labor Health & Human Services & education appropriations bills. | HOUSE OF REPRESENTATIVES,SENATE | 25000 | 0 | 0 | 2017-07-17T17:02:08.470000-04:00 | |
| 1990394 | ROCK & ASSOCIATES db3b05c7-3117-49ac-bcb1-12264a2c50e7 | 2A | ROCK & ASSOCIATES | 33545 | PRECISION PHARMACY | 2017 | second_quarter | PHA | Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. H.R. 2871, Patient Access to Compounded Medications Act of 2017. | HOUSE OF REPRESENTATIVES,SENATE | 11250 | 0 | 0 | 2017-07-17T19:03:39.387000-04:00 | |
| 1990605 | DAVE KOLBE CONSULTING 37330c5e-d1dc-45ad-bab8-9b01e235e6f8 | Q2 | DAVE KOLBE CONSULTING | 401104329 | PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION | 2017 | second_quarter | PHA | Medicare Part-D rebates Trade agreements Patent reform issues | HOUSE OF REPRESENTATIVES,SENATE | 20000 | 0 | 0 | 2017-07-18T08:49:45.667000-04:00 | |
| 1990720 | KING & SPALDING LLP 961401e7-5ec9-440e-8615-86611f3549ef | Q2 | KING & SPALDING LLP | 21632 | SUMITOMO PHARMA AMERICA (FORMERLY SUNOVION PHARMACEUTICALS, INC.) | 2017 | second_quarter | PHA | Issues related to inclusion of prescription drugs within Essential Health Benefit and mental health coverage expansion | HOUSE OF REPRESENTATIVES,SENATE | 0 | 0 | 2017-07-18T09:51:17.800000-04:00 | ||
| 1990746 | TRAVERE THERAPEUTICS 06dd84cb-d3f6-4b91-8875-64ffcd0e3e1a | Q2 | TRAVERE THERAPEUTICS | 401104190 | TRAVERE THERAPEUTICS | 2017 | second_quarter | PHA | Orphan Drug Act, Drug Quality and Security Act drug safety issues, drug pricing, Prescription Drug User Fee Act reauthorization, FAST Generics and CREATES Acts, FDA issues | HOUSE OF REPRESENTATIVES,SENATE | 140000 | 0 | 0 | 2017-07-18T09:55:26.940000-04:00 | |
| 1990779 | HEALTHCARE DISTRIBUTION ALLIANCE(HDA)(FORMERLY HEALTHCARE DISTRIBUTION MANAGEMENT ASSOCIATION (HDMA) d67c1753-78ec-4e3b-9154-00a8d5c361e4 | Q2 | HEALTHCARE DISTRIBUTION ALLIANCE(HDA)(FORMERLY HEALTHCARE DISTRIBUTION MANAGEMENT ASSOCIATION (HDMA) | 28776 | HEALTHCARE DISTRIBUTION ALLIANCE (FORMERLY - HDMA) | 2017 | second_quarter | PHA | Rx Pedigree (Public Law 113-54); Ensuring Patient Access and Effective Enforcement Act (Public Law 114-145); Prescription Drug Abuse - General issues related to Rx drug abuse; Importation of Prescription Drugs (S 469, S 771, HR 1776, HR 1245, HR 934, HR 1480, S 92, S 64), Implementation of Public Law 113-54 (DSCSA) | Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 302000 | 0 | 0 | 2017-07-18T10:02:47.770000-04:00 | |
| 1990797 | THORN RUN PARTNERS feb402ef-8c59-4d96-b911-f865ae8ddac2 | Q2 | THORN RUN PARTNERS | 400534596 | EXPRESS SCRIPTS, INC. | 2017 | second_quarter | PHA | Pharmacy benefits manager standards under the Medicare prescription drug program to further transparency of payment methodologies to pharmacies. Issues related to a pilot program in TRICARE that would establish Department of Defense (DoD) acquisition cost parity for prescription drugs obtained at community pharmacies. Drug reimbursement and general pharmacy related issues. S.637, Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017; issues related to transparency of pharmacy benefit managers (PBMs). | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2017-07-18T10:10:00.567000-04:00 | |
| 1991266 | MASSACHUSETTS MEDICAL SOCIETY 9524e962-b455-4ab3-87a3-061becba9b46 | Q2 | MASSACHUSETTS MEDICAL SOCIETY | 23975 | MASSACHUSETTS MEDICAL SOCIETY | 2017 | second_quarter | PHA | S. 771 - Improving Access to Affordable Prescription Drugs - Legislation that seeks to address prescription drug costs by increasing transparency and accountability, boosting access and affordability of key drugs, spurring innovation, and increasing choice and competition by allowing Medicare to negotiate the price of drugs, among other provisions. Efforts to require the manufacturers suggested retail price of prescription drugs in direct to consumer advertising of prescription drugs - no specific bill | Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE | 70000 | 0 | 0 | 2017-07-18T11:52:31.607000-04:00 | |
| 1991270 | ASCENSION HEALTH 9a636286-5008-4eff-81ad-9193a2ca20ba | Q2 | ASCENSION HEALTH | 53301 | ASCENSION HEALTH | 2017 | second_quarter | PHA | Drug pricing; Creating and Restoring Equal Access to Equivalent Samples Act of 2016 (CREATES) FAIR Drug Pricing Act | Centers For Medicare and Medicaid Services (CMS),Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 248000 | 0 | 0 | 2017-07-18T11:53:34.453000-04:00 | |
| 1991656 | WINNING STRATEGIES WASHINGTON fca37d82-3d97-4fd0-9d2c-92c4260e4d01 | Q2 | WINNING STRATEGIES WASHINGTON | 50796 | KALEO | 2017 | second_quarter | PHA | Pharmaceutical drug development including epinephrine for anaphylaxis | HOUSE OF REPRESENTATIVES,Office of Natl Drug Control Policy (NDCP),SENATE | 30000 | 0 | 0 | 2017-07-18T13:25:31.510000-04:00 | |
| 1991684 | CONSUMER HEALTHCARE PRODUCTS ASSOCIATION a7667959-d663-4d46-b9ea-5152afa4cb29 | Q2 | CONSUMER HEALTHCARE PRODUCTS ASSOCIATION | 29403 | CONSUMER HEALTHCARE PRODUCTS ASSOCIATION | 2017 | second_quarter | PHA | Pseudoephedrine Potential legislation to implement real-time, stop-sale electronic tracking system for sales of medications containing pseudoephedrine in order to preserve consumer access to the ingredient, common in popular cold and allergy medications (no bill number) and oppose prescription requirement (no bill number). Oral Contraceptives H.R. 421/S. 93 - Allowing Greater Access to Safe and Effective Contraception Act of 2017. Grants priority review of applications to switch oral contraceptive drugs from prescription to nonprescription (over-the-counter) status; all sections. Over-the-counter (OTC) medicines; Manufacturing and importation of OTC drugs; Mandatory recall authority of the FDA; Rx-to-OTC Switch Supporting a process within FDA that ensures clarity and timely outcomes for the FDA, applicants and stakeholders, as well as utilizing existing technologies to further streamline the prescription-to-nonprescription switch application process without changing the existing clear distinction between prescription and nonprescription medicines. | Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE,Treasury, Dept of | 215000 | 0 | 0 | 2017-07-18T13:28:45.493000-04:00 | |
| 1991818 | TARPLIN, DOWNS & YOUNG, LLC af8b7066-30ba-47ee-92a8-c7a9919e9f3d | Q2 | TARPLIN, DOWNS & YOUNG, LLC | 304736 | ASTRAZENECA | 2017 | second_quarter | PHA | PL 114-255 - 21st Century Cures, implementation H.R. 2430 - FDA Reauthorization Act of 2017 ***, no specific bill(s), Import Safety, drug development policy, drug shortages, supply chain integrity, Innovation, reimportation | Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2017-07-18T13:49:12.200000-04:00 | |
| 1992021 | BLUECROSS BLUESHIELD OF TENNESSEE 89bddcc8-6b76-4b16-8945-25ada3bd81e6 | Q2 | BLUECROSS BLUESHIELD OF TENNESSEE | 6440 | BLUECROSS BLUESHIELD OF TENNESSEE | 2017 | second_quarter | PHA | General pharmacy and pharmaceutical issues; Opioid Abuse; prescription drug pricing | Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2017-07-18T14:21:50.610000-04:00 | |
| 1992114 | ALKERMES, INC. a0d66aa1-63d0-4e8b-a168-d34ddd1e1de8 | Q2 | ALKERMES, INC. | 400458235 | ALKERMES, INC. | 2017 | second_quarter | PHA | Public law #114-198, Cures Opioid Funding Implementation H.R. 2430 FDA Reauthorization Act of 2017 S.934 FDA Reauthorization Act of 2017 | Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Justice, Dept of (DOJ),Natl Institutes of Health (NIH),Office of Natl Drug Control Policy (NDCP),SENATE,Substance Abuse & Mental Health Services Administration (SAMHSA),Veterans Affairs, Dept of (VA) | 940000 | 0 | 0 | 2017-07-18T14:36:56.847000-04:00 | |
| 1992566 | FOLEY & LARDNER LLP dfe7601c-16b4-4581-b2ff-33dc62ba7612 | Q2 | FOLEY & LARDNER LLP | 15042 | ENDO USA, INC., A MALLINCKRODT-ENDO COMPANY | 2017 | second_quarter | PHA | FDA issues; Issues relating to prescription drug abuse; Issues relating to CDC guidance for prescribing opioids; Issues relating to removal of FDA unapproved products from the market. | HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2017-07-18T15:21:27.040000-04:00 | |
| 1992671 | AMERICAN PHARMACISTS ASSOCIATION 72dee276-628d-479d-9154-c785ed14cc83 | Q2 | AMERICAN PHARMACISTS ASSOCIATION | 3071 | AMERICAN PHARMACISTS ASSOCIATION | 2017 | second_quarter | PHA | HR 1038, S 413 Improving Transparency and Accuracy in Medicare Part D Spending Act HR 1939 To amend title XVIII of the Social Security Act to ensure equal access of Medicare beneficiaries to community pharmacies in underserved areas as network pharmacies under Medicare prescription drug coverage, and for other purposes. HR 592, S 109 To amend title XVIII of the Social Security Act to provide for coverage under the Medicare program of pharmacist services. HR 1480 Safe and Affordable Drugs from Canada Act of 2017 S 637 Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017 HR 1586 To amend the Federal Food, Drug, and Cosmetic Act to ensure that liquid over-the-counter medications are packaged with appropriate dosage delivery devices and, in the case of such medications labeled for pediatric use, appropriate flow restrictors, and for other purposes. S 778 Prescription Drug Monitoring Act of 2017 HR 934 Personal Drug Importation Fairness Act of 2017 HR 421 Allowing Greater Access to Safe and Effective Contraception Act HR 1436 To provide for reconciliation pursuant to title II of the concurrent resolution on the budget for fiscal year 2017. HR 1245, S 469 To amend the Federal Food, Drug, and Cosmetic Act to allow for the importation of affordable and safe drugs by wholesale distributors, pharmacies, and individuals. HR 3268 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2018 (drug compounding provisions) S 1079 Protecting Americans from Dangerous Opioids Act HR 2430 FDA Reauthorization Act of 2017 HR 2567 Access to Birth Control Act HR 2871 Preserving Patient Access to Compounded Medications Act of 2017 HR 2063 Opioid PACE Act of 2017 S 1003 A bill to amend title XIX of the Social Security Act to add standards for drug compendia for physician use for purposes of Medicaid payment for certain drugs, and for other purposes HR 1939/S 1044 Ensuring Seniors Access to Local Pharmacies Act of 2017 | HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2017-07-18T15:34:41.917000-04:00 | |
| 1992834 | FOLEY & LARDNER LLP 4b9bccfb-b50c-4530-9879-d86b6b192fe1 | Q2 | FOLEY & LARDNER LLP | 15042 | PAR PHARMACEUTICAL | 2017 | second_quarter | PHA | FDA issues | HOUSE OF REPRESENTATIVES,SENATE | 0 | 0 | 2017-07-18T15:55:44.480000-04:00 | ||
| 1992918 | CARD & ASSOCIATES, LLC bac11409-b276-42ef-a9fe-c6f7dc327de4 | Q2 | CARD & ASSOCIATES, LLC | 84217 | AMAZON.COM (FRA PILLPACK AN AMAZON COMPANY) | 2017 | second_quarter | PHA | Educate Members on pharmacy contracting with pharmacy benefit managers H.R. 1316 Prescription Drug Price Transparency Act S. 637 Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017 | HOUSE OF REPRESENTATIVES,SENATE | 45000 | 0 | 0 | 2017-07-18T16:07:37.607000-04:00 | |
| 1993193 | GREATER NEW YORK HOSPITAL ASSOCIATION 891f5c91-ec63-4856-8e0d-9002d12a3f20 | Q2 | GREATER NEW YORK HOSPITAL ASSOCIATION | 16830 | GREATER NEW YORK HOSPITAL ASSOCIATION | 2017 | second_quarter | PHA | Preserving access to group purchasing organizations (GPOs) and protecting the GPO safe harbor; educating policymakers on hospital drug shortages and significant drug price increases. Support drug pricing legislation that would promote competition by fast tracking generic drug applications (H.R. 749/S.297). Oppose legislation that would harm the 340B drug discount program for safety net hospitals. | Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Drug Enforcement Administration (DEA),Environmental Protection Agency (EPA),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),Homeland Security, Dept of (DHS),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE,Substance Abuse & Mental Health Services Administration (SAMHSA),White House Office | 540000 | 0 | 0 | 2017-07-18T16:39:13.110000-04:00 | |
| 1993201 | SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING b0fe8814-d1cb-424e-a246-a3463fd21771 | Q2 | SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 35968 | SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2017 | second_quarter | PHA | Compounding of radiopharmaceuticals. | Centers For Medicare and Medicaid Services (CMS),Energy, Dept of,Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,Nuclear Regulatory Commission (NRC),Office of Science & Technology Policy (OSTP),SENATE | 50000 | 0 | 0 | 2017-07-18T16:40:15.720000-04:00 | |
| 1993351 | ACADEMY OF MANAGED CARE PHARMACY c0feb6ac-cee5-45d0-bc59-d85bc8ba1ad2 | Q2 | ACADEMY OF MANAGED CARE PHARMACY | 48793 | ACADEMY OF MANAGED CARE PHARMACY | 2017 | second_quarter | PHA | Letters of support for the CREATES Act (H.R. 2212 and S. 974), the FAST Act (H.R. 2051) and the Pharmaceutical Information Exchange Act(H.R. 2026). Comments to FDA on biosimilars and interchangeability, | Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 70000 | 0 | 0 | 2017-07-18T17:08:57.550000-04:00 | |
| 1993366 | TARPLIN, DOWNS & YOUNG, LLC 9bbad209-3533-4955-bffc-b136bfcc8721 | Q2 | TARPLIN, DOWNS & YOUNG, LLC | 304736 | PHRMA | 2017 | second_quarter | PHA | PL 114-255 - 21st Century Cures, implementation H.R. 1628 - American Health Care Act of 2017 ***, no specific bill(s), prescription drug importation, import safety, supply chain integrity, Prescription Drug User Fee Act Fee Reauthorization and associated policies, user fee sequester, innovation | Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 80000 | 0 | 0 | 2017-07-18T17:13:04.803000-04:00 | |
| 1993398 | PRIME THERAPEUTICS 1f58811f-1516-40e0-91d8-e8049aa3de50 | Q2 | PRIME THERAPEUTICS | 400339576 | PRIME THERAPEUTICS | 2017 | second_quarter | PHA | H.R.2430/S.934: FDA Reauthorization Act of 2017--provisions to ensure greater market competition for generics & biosimilars. S.469/H.R.1245: Affordable and Safe Prescription Drug Importation Act --issues relating to noninterference and workability. S.778: Prescription Drug Monitoring Act--issues related to dispensers access to PDMP data across state lines. S.771/H.R.1776: Improving Access to Affordable Prescription Drugs Act--issues related to ensuring a competitive marketplace for prescription drugs. H.R.1939/S.1044: Ensuring Seniors Access to Local Pharmacies Act of 2017 (any willing pharmacy bill)--Provisions limiting payers' ability to selectively contract. Use of prescription drug coupons in federal programs and the ACA exchanges and their effects on insurance premiums. S.1003: To amend title XIX of the Social Security Act to add standards for drug compendia for physician use for purposes of Medicaid payment for certain drugs, and for other purposes; provisions related do drug coverage in Medicare and Medicaid. H.R.1703: Medical Product Communications Act of 2017--provisions relating to greater market access for off-label indications. | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2017-07-18T17:24:28.943000-04:00 | |
| 1993426 | THE INGRAM GROUP LLC 285785fa-2a22-4c14-8566-d39c971e118d | Q2 | THE INGRAM GROUP LLC | 400577737 | ELI LILLY AND COMPANY | 2017 | second_quarter | PHA | General issues related to the biopharmaceutical and pharmaceutical industries including drug importation. H.R.1628, American Health Care Act of 2017/Better Care Reconciliation Act of 2017. | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2017-07-18T17:32:50.617000-04:00 | |
| 1993445 | APOTEX CORP. b90e200b-d219-4003-896a-b4a08e5d399e | Q2 | APOTEX CORP. | 310973 | APOTEX CORP. | 2017 | second_quarter | PHA | HR 2430, the FDA Reauthorization Act of 2017, Title VIII, Improving Generic Drug Access, provisions relating to enhancing the generic drug approval process, spurring the development and approval of generic versions of drugs with limited competition, and generic drug exclusivity; S. 934, the FDA Reauthorization Act of 2017, Title IX, Generic Drug Access, provisions relating to enhancing the generic drug approval process and spurring the development and approval of generic versions of drugs with limited competition; HR 2212, the Creating and Restoring Equal Access to Equivalent Samples Act of 2017, provisions relating to the provision of brand drug products by brand manufacturers to generic manufacturers for development testing, and for shared Risk Evaluation and Mitigation (REMS) programs for brand and generic pharmaceuticals; S. 974, the Creating and Restoring Equal Access to Equivalent Samples Act of 2017, provisions relating to the provision of brand drug products by brand manufacturers to generic manufacturers for development testing, and for shared Risk Evaluation and Mitigation (REMS) programs for brand and generic pharmaceuticals; HR 2051, the Fair Access for Safe and Timely Generic Act of 2017, provisions relating to the provision of brand drug products by brand manufacturers to generic manufacturers for development testing, and for shared Risk Evaluation and Mitigation (REMS) programs for brand and generic pharmaceuticals; and Federal policy related to repealing Section 603, Applying the Medicaid additional rebate requirement to generics, of Public Law No 114-67, the Bipartisan Budget Act of 2015 | HOUSE OF REPRESENTATIVES,SENATE | 300000 | 0 | 0 | 2017-07-18T17:40:11.930000-04:00 | |
| 1993454 | KOUNTOUPES DENHAM CARR & REID, LLC 097532e5-4a24-4429-ba9a-fb1e7bfe6d3a | Q2 | KOUNTOUPES DENHAM CARR & REID, LLC | 320918 | CONSUMER HEALTHCARE PRODUCTS ASSOCIATION | 2017 | second_quarter | PHA | General issues related to over the counter pharmaceuticals, cosmetics issues related to Rx/OTC transition issues related to draft legislation addressing the over the counter drug monograph process, and H. R. 2430, the FDA Reauthorization Act (FDARA) of 2017. | Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2017-07-18T17:42:18.900000-04:00 | |
| 1993683 | THORSEN FRENCH ADVOCACY LLC 611ad2ac-40b8-4c3a-895d-37ba60d40382 | Q2 | THORSEN FRENCH ADVOCACY LLC | 400599826 | CARDINAL HEALTH, INC. | 2017 | second_quarter | PHA | Issues related to prescription drug abuse. Issues related to pharmaceutical market value. | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2017-07-18T20:40:59.220000-04:00 | |
| 1993700 | THORSEN FRENCH ADVOCACY LLC 955aa0d7-bd72-43c8-a5e5-451b4c00499f | Q2 | THORSEN FRENCH ADVOCACY LLC | 400599826 | HEALTHCARE DISTRIBUTION ALLIANCE | 2017 | second_quarter | PHA | General issues related to prescription drug abuse. Issues related to pharmaceutical market value. Prescription drug importation. | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2017-07-18T20:54:12.327000-04:00 | |
| 1993710 | THORSEN FRENCH ADVOCACY LLC 96d07d94-e754-4d6b-93aa-d55d04f963ff | Q2 | THORSEN FRENCH ADVOCACY LLC | 400599826 | PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | 2017 | second_quarter | PHA | Issues related to pharmaceutical market value. Issues related to prescription drug abuse. H.R.2212: CREATES Act of 2017. | HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2017-07-18T21:01:22.767000-04:00 | |
| 1993835 | DAIICHI SANKYO, INC. cf66dd7b-4193-4c3b-aad9-e8ec94cfa540 | Q2 | DAIICHI SANKYO, INC. | 316731 | DAIICHI SANKYO INC | 2017 | second_quarter | PHA | H.R.2025, Abuse-Deterrent Opioids Plan for Tomorrow Act of 2017 H.R.2430 and S.934, FDA Reauthorization Act of 2017 | HOUSE OF REPRESENTATIVES | 150000 | 0 | 0 | 2017-07-18T23:39:05.707000-04:00 | |
| 1994385 | ANIMAL HEALTH INSTITUTE 8667f447-e336-400c-b408-f3efe7bc0eef | Q2 | ANIMAL HEALTH INSTITUTE | 4037 | ANIMAL HEALTH INSTITUTE | 2017 | second_quarter | PHA | Issues related to illegal drug manufacturing under the guise of pharmacy compounding; Issues related to the granting of Categorical Exclusions for animal health products. | Agriculture, Dept of (USDA),HOUSE OF REPRESENTATIVES,SENATE,U.S. Trade Representative (USTR) | 35000 | 0 | 0 | 2017-07-19T09:45:19.420000-04:00 | |
| 1994566 | TRAVERE THERAPEUTICS 030a4f97-e7a9-4db6-9177-e55b11420a48 | 2A | TRAVERE THERAPEUTICS | 401104190 | TRAVERE THERAPEUTICS | 2017 | second_quarter | PHA | Orphan Drug Act, Drug Quality and Security Act drug safety issues, drug pricing, Prescription Drug User Fee Act reauthorization, FAST Generics and CREATES Acts, FDA issues | HOUSE OF REPRESENTATIVES,SENATE | 170000 | 0 | 0 | 2017-07-19T10:19:20.580000-04:00 | |
| 1994921 | BUCHANAN INGERSOLL & ROONEY PC dc95950d-8027-43bc-9ddf-b917ef1e2801 | Q2 | BUCHANAN INGERSOLL & ROONEY PC | 55291 | WOMEN'S CHOICE PHARMACEUTICALS, LLC | 2017 | second_quarter | PHA | Development of government relations strategy relating to prenatal dietary supplements. | HOUSE OF REPRESENTATIVES,SENATE | 10000 | 0 | 0 | 2017-07-19T11:00:03.663000-04:00 | |
| 1994925 | AVENUE SOLUTIONS b1f5e704-50cd-4740-901e-a3d798fb6de1 | Q2 | AVENUE SOLUTIONS | 72111 | JAZZ PHARMACEUTICALS, INC. | 2017 | second_quarter | PHA | S. 974, Creating and Restoring Equal Access to Equivalent Samples Act of 2017 (CREATES Act of 2017); H.R. 2051, FAST Generics Act | HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2017-07-19T11:01:06.270000-04:00 | |
| 1995124 | UNIVERSITY OF IOWA b5860689-908c-40d3-85eb-941e77cd48c8 | Q2 | UNIVERSITY OF IOWA | 49191 | UNIVERSITY OF IOWA | 2017 | second_quarter | PHA | FY 17 and FY 18 appropriations for NIH Support for palliative care programs Support for 340B program | Administration for Children & Families (ACF),Agriculture, Dept of (USDA),Centers For Medicare and Medicaid Services (CMS),Defense, Dept of (DOD),Education, Dept of,Energy, Dept of,Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),Office of Management & Budget (OMB),SENATE,State, Dept of (DOS),Transportation, Dept of (DOT) | 86662 | 0 | 0 | 2017-07-19T11:19:05.057000-04:00 | |
| 1995302 | FTI GOVERNMENT AFFAIRS 2de028ac-bd06-4984-89c3-c46acdbd25a9 | Q2 | FTI GOVERNMENT AFFAIRS | 401054971 | PROFESSIONAL COMPOUNDING CENTERS OF AMERICA | 2017 | second_quarter | PHA | Implementation of The Drug Quality and Security Act, H.R.3204 (Public Law) ((USP/NF Monograph)). Monitor H.R.2871 "Preserving Patient Access to Compounded Medication Act of 2017. " | HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2017-07-19T11:33:56.120000-04:00 | |
| 1995338 | SC PARTNERS LLC 5860dfdd-0550-458b-9e62-04c9f9a2cf45 | Q2 | SC PARTNERS LLC | 318994 | PFIZER, INC. | 2017 | second_quarter | PHA | Advocated for maintaining a safe prescription drug supply, and shared concerns about the safety and economic implications of allowing the importation of prescription drugs and biologics from Canada and other countries. Affordable and Safe Prescription Drug Importation Act (S. 469) | HOUSE OF REPRESENTATIVES,SENATE | 20000 | 0 | 0 | 2017-07-19T11:36:26.087000-04:00 | |
| 1995445 | TARPLIN, DOWNS & YOUNG, LLC 8e4ec86f-5955-4484-87cc-f57ea25b290c | Q2 | TARPLIN, DOWNS & YOUNG, LLC | 304736 | BIOTECHNOLOGY INDUSTRY ORGANIZATION | 2017 | second_quarter | PHA | PL 114-255 - 21st Century Cures, implementation H.R. 2430 - FDA Reauthorization Act of 2017 ***, no specific bill(s), Drug Safety, Prescription Drug Importation, Import Safety, supply chain integrity, biosimilars, PDUFA and associated policies, patent settlements, accelerated approval, break through therapies, compounding, user fee reauthorization, Innovation | Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE | 80000 | 0 | 0 | 2017-07-19T11:46:43.857000-04:00 | |
| 1995670 | MASS GENERAL BRIGHAM (FORMERLY KNOWN AS PARTNERS HEALTHCARE) d74eca28-9b5a-436d-a4ac-b621f9e437fb | Q2 | MASS GENERAL BRIGHAM (FORMERLY KNOWN AS PARTNERS HEALTHCARE) | 400265214 | MASS GENERAL BRIGHAM (FORMERLY KNOWN AS PARTNERS HEALTHCARE) | 2017 | second_quarter | PHA | Pricing, shortages, and safety issues | Centers For Medicare and Medicaid Services (CMS),Defense, Dept of (DOD),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE | 137625 | 0 | 0 | 2017-07-19T12:14:16-04:00 | |
| 1995725 | FORGE FEDERAL AFFAIRS LLC 91b075d2-d59d-4f83-ab2a-9599cdebf2c8 | Q2 | FORGE FEDERAL AFFAIRS LLC | 400865535 | LILLY USA LLC | 2017 | second_quarter | PHA | Issues related to pricing of prescription drugs. Opposition to prescription drug importation. Support for funding of Department of Homeland Security drug interdiction efforts. Issues related to reauthorization of the Prescription Drug User Fee Act. H.R.2430/S.934, FDA Reauthorization Act of 2017. | HOUSE OF REPRESENTATIVES,SENATE | 20000 | 0 | 0 | 2017-07-19T12:19:53.483000-04:00 | |
| 1995868 | AMERICAN ASSOCIATION FOR JUSTICE 29b88846-1f22-450d-96a4-bc0671976bef | Q2 | AMERICAN ASSOCIATION FOR JUSTICE | 4733 | AMERICAN ASSOCIATION FOR JUSTICE | 2017 | second_quarter | PHA | S. 204/H.R. 878 (Trickett Wendler Right to Try Act of 2017); authorizes the use of unapproved medical products by patients diagnosed with a terminal illness in accordance with State law. S. 469/H.R. 1245 (Affordable and Safe Prescription Drug Importation Act); amends the Federal Food, Drug, and Cosmetic Act to allow for the importation of affordable and safe drugs by wholesale distributors. S. 670/H.R. 1652 (Over-the-Counter Hearing Aid Act of 2017); provides for the regulation of over-the-counter hearing aids. S. 297/H.R. 749 (Increasing Competition in Pharmaceuticals Act/Lower Drug Costs through Competition Act); amends the Federal Food, Drug, and Cosmetic Act to revise provisions regarding review and approval of generic drug applications or supplements to generic drug applications for drugs in some circumstances. General Lobbying with regard to the preemption of states causes of action involving medical device and drug manufacturers. General lobbying with regard to off label promotion of pharmaceutical products. General lobbying with regard to pharmaceutical drug advertising. General lobbying with regard to pharmaceutical price-gouging. Lobbying with regard to biosimilar naming and labeling. Lobbying with regard to updating generic drug labeling responsibilities. | Consumer Financial Protection Bureau (CFPB),HOUSE OF REPRESENTATIVES,SENATE | 1940000 | 0 | 0 | 2017-07-19T12:36:24.143000-04:00 | |
| 1996113 | MERCURY PUBLIC AFFAIRS, LLC 582b708e-eb7c-4f45-9855-6ab929cafb31 | Q2 | MERCURY PUBLIC AFFAIRS, LLC | 70175 | KALISPELL REGIONAL HEALTHCARE | 2017 | second_quarter | PHA | Veteran pharmacy issues and polices | Federal Communications Commission (FCC),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,Veterans Affairs, Dept of (VA) | 30000 | 0 | 0 | 2017-07-19T13:15:02.663000-04:00 | |
| 1996301 | BUCHANAN INGERSOLL & ROONEY PC 6c606795-50f4-4ab0-9395-23ec8e4365a4 | Q2 | BUCHANAN INGERSOLL & ROONEY PC | 55291 | TONIX PHARMACEUTICALS HOLDING CORP. | 2017 | second_quarter | PHA | Federal funding related to clinical trials for military PTSD; FY 2018 NDAA and Defense Appropriations | HOUSE OF REPRESENTATIVES,SENATE | 40000 | 0 | 0 | 2017-07-19T13:30:43.243000-04:00 | |
| 1996492 | TARPLIN, DOWNS & YOUNG, LLC 4cd9c9d2-c6f6-4286-b5ea-56a089243e18 | Q2 | TARPLIN, DOWNS & YOUNG, LLC | 304736 | HEALTHCARE DISTRIBUTION ALLIANCE (HEALTHCARE DISTRIBUTION MANAGMENT ASSN.) | 2017 | second_quarter | PHA | Importation of prescription drugs (S. 469, S. 771, H.R. 1776, H.R. 1245, H.R. 934, H.R. 1480, S. 92, S. 64) Rx Pedigree (PL 113-54) Prescription Drug Monitoring Programs (S. 480, H.R. 1725) Prescription Drug Abuse - General issues related to Rx drug abuse Ensuring Patient Access and Effective Enforcement Act (PL 114-145) Implementation of Public Law 113-54 (DSCSA) | Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE | 80000 | 0 | 0 | 2017-07-19T13:46:40.697000-04:00 | |
| 1996606 | ELI LILLY AND COMPANY 5bbd7163-7bea-43db-8ec9-befede69e9d0 | Q2 | ELI LILLY AND COMPANY | 13392 | ELI LILLY AND COMPANY | 2017 | second_quarter | PHA | Hospital discounts; 340B program | Agriculture, Dept of (USDA),Commerce, Dept of (DOC),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Homeland Security, Dept of (DHS),HOUSE OF REPRESENTATIVES,Justice, Dept of (DOJ),Natl Institutes of Health (NIH),Office of Management & Budget (OMB),SENATE,State, Dept of (DOS),U.S. Trade Representative (USTR) | 2020000 | 0 | 0 | 2017-07-19T13:52:38.417000-04:00 | |
| 1996981 | OREGON HEALTH & SCIENCE UNIVERSITY cdf58f4d-4226-4a04-8106-dd799a90c9d9 | Q2 | OREGON HEALTH & SCIENCE UNIVERSITY | 30291 | OREGON HEALTH & SCIENCE UNIVERSITY | 2017 | second_quarter | PHA | 340b Drug Discount Program for safety net hospitals and Health Resources and Services Administration proposed omnibus guidance. | HOUSE OF REPRESENTATIVES,SENATE | 70000 | 0 | 0 | 2017-07-19T14:18:07.810000-04:00 | |
| 1997180 | BLUE CROSS AND BLUE SHIELD ASSOCIATION fb352986-5f32-4e7d-b839-dae15aabe954 | Q2 | BLUE CROSS AND BLUE SHIELD ASSOCIATION | 6358 | BLUE CROSS AND BLUE SHIELD ASSOCIATION | 2017 | second_quarter | PHA | Opioid Abuse; Drug Pricing; HR 2026 Pharmaceutical Information Exchange Act Introduced April 6, 2017 by Brett Guthrie (R-VA) To improve patient access to emerging medication therapies by clarifying the scope of permitted health care economic and scientific information communications between biopharmaceutical manufacturers and population health decision makers. HR 2051 FAST Generics Act Introduced April 6, 2017 by David McKinley (R-WV) To amend the Federal Food, Drug, and Cosmetic Act to ensure that eligible product developers have competitive access to approved drugs and licensed biological products,so as to enable eligible product developers to develop and test new products, and for other purposes. | Centers For Medicare and Medicaid Services (CMS),Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE,Treasury, Dept of,Vice President of the U.S.,White House Office | 2050000 | 0 | 0 | 2017-07-19T14:29:41.343000-04:00 | |
| 1997391 | AVENUE SOLUTIONS 98a5e82d-c709-4551-a8b3-7c92f9ac2280 | Q2 | AVENUE SOLUTIONS | 72111 | MOMENTA PHARMACEUTICALS, INC. | 2017 | second_quarter | PHA | Improving access to biogenerics | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2017-07-19T14:51:18.890000-04:00 | |
| 1997477 | POLITICAL CAPITAL, LLC 8fbd6145-9eb3-45b2-9afb-98ea2514df95 | Q2 | POLITICAL CAPITAL, LLC | 401104260 | MEDISCA INC | 2017 | second_quarter | PHA | DQSA Oversight HR 2871 | Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE | 15000 | 0 | 0 | 2017-07-19T14:56:13.337000-04:00 | |
| 1997487 | AVENUE SOLUTIONS 5b715d12-485d-415a-9e67-fc942ffa8e5f | Q2 | AVENUE SOLUTIONS | 72111 | CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM | 2017 | second_quarter | PHA | Issues related to biosimilars | SENATE | 80000 | 0 | 0 | 2017-07-19T14:57:19.853000-04:00 | |
| 1997655 | ARMORY HILL ADVOCATES (FORMERLY KNOWN AS RAWLSON POLICY GROUP) 5cdc3531-6963-45e6-a0d5-e3c5a3f8c876 | Q2 | ARMORY HILL ADVOCATES (FORMERLY KNOWN AS RAWLSON POLICY GROUP) | 400637926 | ACCREDITATION COMMISSION FOR HEALTH CARE | 2017 | second_quarter | PHA | Legislation & regulations impacting Pharmacy Compounding. | Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE | 5000 | 0 | 0 | 2017-07-19T15:08:13.683000-04:00 |
Advanced export
JSON shape: default, array, newline-delimited, object
CREATE TABLE lobbying_activities (
id INTEGER PRIMARY KEY,
filing_uuid TEXT NOT NULL,
filing_type TEXT NOT NULL,
registrant_name TEXT NOT NULL,
registrant_id INTEGER,
client_name TEXT NOT NULL,
filing_year INTEGER NOT NULL,
filing_period TEXT NOT NULL,
issue_code TEXT,
specific_issues TEXT,
government_entities TEXT,
income_amount INTEGER,
expense_amount INTEGER,
is_no_activity INTEGER DEFAULT 0,
is_termination INTEGER DEFAULT 0,
received_date TEXT,
CONSTRAINT fk_activity_filing FOREIGN KEY (filing_uuid)
REFERENCES lobbying_filings_raw(filing_uuid)
);
CREATE INDEX idx_act_client_name ON lobbying_activities(client_name COLLATE NOCASE);
CREATE INDEX idx_act_issue_code ON lobbying_activities(issue_code);
CREATE INDEX idx_act_filing_year ON lobbying_activities(filing_year);
CREATE INDEX idx_act_filing_uuid ON lobbying_activities(filing_uuid);